UBRELVY® (ubrogepant) tablets 50mg 100mg

RETHINKING MIGRAINE

A balanced discussion about the prevention and treatment of migraine attacks

QULIPTA® (atogepant) tablets

PRESENTED BY:

Wade Cooper, DO
Neurology
Memorial Healthcare
Okemos MI

Thursday, March 13, 2025 at 7:00 PM ET

Please RSVP using the link or QR code below:
https://migrainelive.com/register/213684

For questions, contact your AbbVie Representative
Heather Eick
Phone:
Email: heather.eick@abbvie.com

INDICATION
QULIPTA® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS
Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/qulipta_pi.pdf.

INDICATION
UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS
The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf.

The Phase 3 studies for UBRELVY and QULIPTA that supported product approval had no patients on concomitant medication that acted on the CGRP pathway.

The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure.
AbbVie's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption.
AbbVie abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from AbbVie. Please comply with applicable law.

abbvie